Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre; Matthew James Butler; Isabelle Le; Andrew Brenner

doi:10.1016/j.clml.2019.05.012

Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre, Matthew James Butler, Isabelle Le, Andrew Brenner

Department of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

Original language	English (US)
Pages (from-to)	665-669
Number of pages	5
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	19
Issue number	10
DOIs	https://doi.org/10.1016/j.clml.2019.05.012
State	Published - Oct 2019

Keywords

Consolidation
MTX
PCNSL
R-MPV
TMZ

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2019.05.012

Cite this

@article{692f4ba23e8a4effbc8b99e142d91c83,

title = "Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma",

abstract = "Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.",

keywords = "Consolidation, MTX, PCNSL, R-MPV, TMZ",

author = "Geraldine Faivre and Butler, {Matthew James} and Isabelle Le and Andrew Brenner",

note = "Funding Information: The study was supported by in part by the University of Texas Health Science Center at San Antonio Cancer Therapy and Research Center through the National Institutes of Health; National Cancer Institute P30 award CA054174. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = oct,

doi = "10.1016/j.clml.2019.05.012",

language = "English (US)",

volume = "19",

pages = "665--669",

journal = "Clinical Lymphoma",

issn = "2152-2669",

publisher = "Cancer Media Group",

number = "10",

}

TY - JOUR

T1 - Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

AU - Faivre, Geraldine

AU - Butler, Matthew James

AU - Le, Isabelle

AU - Brenner, Andrew

N1 - Funding Information: The study was supported by in part by the University of Texas Health Science Center at San Antonio Cancer Therapy and Research Center through the National Institutes of Health; National Cancer Institute P30 award CA054174. Publisher Copyright: © 2019

PY - 2019/10

Y1 - 2019/10

N2 - Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

AB - Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

KW - Consolidation

KW - MTX

KW - PCNSL

KW - R-MPV

KW - TMZ

UR - http://www.scopus.com/inward/record.url?scp=85069726281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069726281&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.05.012

DO - 10.1016/j.clml.2019.05.012

M3 - Article

C2 - 31351990

AN - SCOPUS:85069726281

VL - 19

SP - 665

EP - 669

JO - Clinical Lymphoma

JF - Clinical Lymphoma

SN - 2152-2669

IS - 10

ER -

Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this